Soybean Hydrolysate Polypeptides for Cholesterol Esterase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs for lowering cholesterol, such as statins, pose health risks and are less effective, while natural food-derived peptides for cholesterol regulation are not adequately explored.
Innovation Solution
Development of polypeptides from soybean protein hydrolysate with specific molecular docking and bioactivity scores, inhibiting cholesterol esterase to lower blood lipids, prepared through hydrolysis and screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statin drugs are used to lower cholesterol, then cholesterol-lowering effect is improved, but blood sugar increases and diabetes risk increases
Solution Approach 1:
The patent uses natural food-derived peptide fragments as temporary, safe alternatives to statin drugs. These peptides are obtained from soybean protein hydrolysate and provide cholesterol-lowering effects without the harmful side effects of conventional statins, acting as a natural, disposable remedy that avoids long-term dependency and serious side effects
Solution Approach 2:
The patent introduces peptide fragments as intermediary substances between cholesterol and the body's metabolic system. These peptides inhibit cholesterol esterase activity, serving as a natural mediator that regulates cholesterol metabolism without directly interfering with blood sugar metabolism, thus avoiding the diabetes risk associated with statins
2Object-affected harmful factors
If non-statin drugs are used to lower cholesterol, then blood sugar control is maintained, but cholesterol-lowering effectiveness is reduced
Solution Approach 1:
The patent changes the molecular parameters of the active ingredients by identifying and isolating specific peptide fragments with particular amino acid sequences and molecular weights. These parameter changes enable the peptides to bind effectively to cholesterol esterase, achieving potent cholesterol-lowering activity while maintaining blood sugar control, thus overcoming the effectiveness limitation of non-statin drugs
3Reliability
If protein hydrolysis is performed to obtain peptide fragments, then cholesterol-lowering activity is improved, but processing complexity increases
Solution Approach 1:
The patent segments the soybean protein into specific peptide fragments through controlled hydrolysis. By dividing the complex protein into smaller, functional peptide units with identified cholesterol-lowering activity, the process becomes more manageable and the active ingredients easier to isolate and standardize, reducing overall processing complexity while maintaining effectiveness
Solution Approach 2:
The patent extracts the active cholesterol-lowering peptide fragments from the complex protein hydrolysate through systematic filtration and purification. By taking out only the relevant peptide components with cholesterol esterase inhibitory activity, the process simplifies the final product and reduces processing complexity compared to working with the entire protein mixture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified peptides effectively reduce serum cholesterol and triglycerides, demonstrating a significant lipid-lowering effect comparable to statin drugs, suitable for pharmaceutical and food applications.
Implementation Method 1
hydrolyzing a soybean protein with a protease to obtain the protein hydrolysate
Implementation Method 2
Inhibiting the hydrolytic activity of cholesterol esterase can effectively reduce serum cholesterol, thereby lowering blood lipids
Data Source
AI summary
The present disclosure provides polypeptides having a cholesterol-lowering function in a soybean protein hydrolysate, a preparation method thereof, and uses thereof. The polypeptides are derived from peptide fragments having a molecular docking “binding energy” value of less than −1.2 kcal with cholesterol esterase. The peptide fragments of the polypeptides that are subjected to molecular docking with cholesterol esterase are derived from 23 polypeptides having a Peptide Ranker bioactivity score of greater than 0.9. The polypeptides possess a significant blood-lipid-lowering function.